Design and Synthesis of Some New Quinoxaline-Thiazole-Benzamide Hybrids: In Vitro Anticancer Activity and Their Molecular Docking Studies

Abstract

Objective: The quinoxaline compound with molecular formula C₈H₆N₂O, which shows a wide range of biological activities including antiviral, anticancer, antimicrobial, antituberculosis, and antileishmanial. Methods: As a part of our efforts to design new anticancer agents, in this study, we develop quinoxaline-thiazole-benzamide hybrids. The anticancer evolution of these hybrids was studied using the MTT assay method. Results and Discussion: The anticancer activity results exhibit that three compounds, 3,5-dimethoxy-N-(4-(2-oxo-1,2-dihydroquinoxaline-1-carbonyl)thiazol-2-yl)benzamide, 4-methoxy-N-(4-(2-oxo-1,2-dihydroquinoxa line-1-carbonyl)thiazol-2-yl)benzamide, and 3,4-dimethoxy-N-(4-(2-oxo-1,2-dihydroquinoxaline-1-carbonyl)thiazol-2-yl)benzamide were shown remarkable anticancer activity ranging from 1.23 to 1.96 µM, demonstrating greater potency than the standard drug. Conclusions: Finally, the in silico results are strongly supported by in vitro anticancer activity data and tyrosine kinase EGFR inhibitory activity assay results.